Thromboprophylaxis for outpatients with COVID-19: a Systematic Review and Meta-analysis
Journal of Thrombosis and Thrombolysis · 2024
DOI: 10.1007/s11239-024-02966-3 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2024. Verfasst von Cho-Han Chiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA. Hauptthemen laut MEDLINE: COVID-19, Venous Thromboembolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Patients with COVID-19 develop an increased risk of thromboembolism. Thromboprophylaxis is recommended for hospitalized COVID-19 patients, but the role of thromboprophylaxis in outpatients with COVID-19 is less well defined. We conducted a systematic review and meta-analysis to evaluate the safety and efficacy of thromboprophylaxis among outpatients with COVID-19. We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus from inception to August 2023. The outcomes of interest were venous thromboembolic events including deep venous thrombosis and pulmonary embolism, all-cause mortality, cardiovascular events, hospitalization, major bleeding events, and non-major bleeding events. We included 6 trials comprising 3352 patients. Patients who received thromboprophylaxis had an approximately 70% reduction in venous thromboembolism (RR, 0.28 [95% CI, 0.08 to 0.93]) compared to patients who did not receive thromboprophylaxis. The risk of mortality (RR, 0.79 [95% CI, 0.35 to 1.77]), cardiovascular events (RR, 0.91 [95% CI, 0.30 to 2.73]), and hospitalization (RR, 1.09 [95% CI, 0.81 to 1.47]) were similar between the two groups. Patients who received thromboprophylaxis had a higher risk of non-major bleeding (RR, 3.48 [95% CI, 1.72 to 7.05) compared to patients who did not receive thromboprophylaxis. Thromboprophylaxis reduced the risk of venous thromboembolism but not mortality, cardiovascular events, or hospitalization among outpatients with COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA.
- Department of Medicine, Unity Hospital, Rochester Regional Health, Rochester, NY, USA.
- Department of Medicine, Yale New Haven Hospital, New Haven, CT, USA.
- Department of Medicine, Danbury Hospital, Danbury, CT, USA.
- Harvard Graduate School of Education, Cambridge, MA, USA.
- Department of Environmental and Occupational Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Zitieren
APA
Chiang, C. H., Ahmed, O., Liu, W., See, X. Y., Chang, Y. C., Peng, C. Y., Wang, Z., Chiang, C. H., Hsia, Y. P., & Chiang, C. H. (2024). Thromboprophylaxis for outpatients with COVID-19: a Systematic Review and Meta-analysis. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-024-02966-3
Vancouver
Chiang CH, Ahmed O, Liu W, See XY, Chang YC, Peng CY, et al. Thromboprophylaxis for outpatients with COVID-19: a Systematic Review and Meta-analysis. Journal of Thrombosis and Thrombolysis. 2024. doi:10.1007/s11239-024-02966-3
BibTeX
@article{Chiang2024,
author = {Chiang, Cho-Han and Ahmed, Omer and Liu, Weitao and See, Xin Ya and Chang, Yu-Cheng and Peng, Chun-Yu and Wang, Zihan and Chiang, Cho-Hsien and Hsia, Yuan Ping and Chiang, Cho-Hung},
title = {Thromboprophylaxis for outpatients with COVID-19: a Systematic Review and Meta-analysis},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2024},
doi = {10.1007/s11239-024-02966-3}
}
EUVIMED